BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 23540866)

  • 41. An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer.
    Sandler A; Graham C; Baggstrom M; Herbst R; Zergebel C; Saito K; Jones D
    J Thorac Oncol; 2011 Aug; 6(8):1400-6. PubMed ID: 21673602
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.
    Yuan S; Sun X; Li M; Yu J; Ren R; Yu Y; Li J; Liu X; Wang R; Li B; Kong L; Yin Y
    Am J Clin Oncol; 2007 Jun; 30(3):239-44. PubMed ID: 17551299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [UFT plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer--its application to outpatient practice].
    Yano T; Koga T; Nomiyama H; Hidaka H
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):959-62. PubMed ID: 12894710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
    De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
    J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer.
    De Leyn P; Vansteenkiste J; Lievens Y; Van Raemdonck D; Nafteux P; Decker G; Coosemans W; Decaluwé H; Moons J; Lerut T
    J Thorac Oncol; 2009 Jan; 4(1):62-8. PubMed ID: 19096308
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study.
    Beckmann G; Fietkau R; Huber RM; Kleine P; Schmidt M; Semrau S; Aubert D; Fittipaldo A; Flentje M
    Onkologie; 2006 Apr; 29(4):137-42. PubMed ID: 16601369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.
    Maguire J; Khan I; McMenemin R; O'Rourke N; McNee S; Kelly V; Peedell C; Snee M
    Eur J Cancer; 2014 Nov; 50(17):2939-49. PubMed ID: 25304298
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
    Fujii M; Tomita K; Nishijima W; Tsukuda M; Hasegawa Y; Ishitoya J; Yamane H; Homma A; Tomita T
    Jpn J Clin Oncol; 2010 Mar; 40(3):214-21. PubMed ID: 19934112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer.
    Li BS; Gong HY; Huang W; Yi Y; Yu JM; Wang ZT; Zhang ZC; Sun HF; Li HS; Wang LY
    Am J Clin Oncol; 2012 Apr; 35(2):115-9. PubMed ID: 21555933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
    Ichinose Y; Yoshimori K; Sakai H; Nakai Y; Sugiura T; Kawahara M; Niitani H
    Clin Cancer Res; 2004 Dec; 10(23):7860-4. PubMed ID: 15585618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial.
    Poudenx M; Bondiau PY; Chamorey E; Venissac N; Otto J; Pourel N; Castelnau O; Tessier E; De Surmont Salasc B; Berdah JF; Pop D; Michel C; Mouroux J
    Oncology; 2012; 83(6):321-8. PubMed ID: 22986621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
    Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
    Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
    Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer.
    Taira T; Yoh K; Nagase S; Kubota K; Ohmatsu H; Niho S; Onozawa M; Akimoto T; Ohe Y; Goto K
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):565-572. PubMed ID: 29387962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.
    Shinchi H; Maemura K; Mataki Y; Kurahara H; Sakoda M; Ueno S; Hiraki Y; Nakajo M; Natsugoe S; Takao S
    J Hepatobiliary Pancreat Sci; 2012 Mar; 19(2):152-8. PubMed ID: 21647560
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study.
    Nawrocki S; Krzakowski M; Wasilewska-Tesluk E; Kowalski D; Rucinska M; Dziadziuszko R; Sowa A
    J Thorac Oncol; 2010 Aug; 5(8):1255-62. PubMed ID: 20592630
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
    Niho S; Yoshida T; Akimoto T; Sakamaki K; Ono A; Seto T; Nishio M; Yamamoto N; Hida T; Okamoto H; Kurata T; Satouchi M; Goto K; Yamanaka T; Ohe Y
    Lung Cancer; 2020 Mar; 141():64-71. PubMed ID: 31955002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.